Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration

Drug Metabolism and Disposition

Volumn 30, Issue 12, 2002, Pages 1455-1461

  Lu, Jian Feng ^a,b   Blaschke, Terrence F ^c   Flexner, Chables ^d   Rosenkranz, Susan L ^e   Sheiner, Lewis B ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR; RITONAVIR; SAQUINAVIR; CYP3A PROTEIN, HUMAN; CYTOCHROME P450;

ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; LIVER CLEARANCE; NORMAL HUMAN; PRIORITY JOURNAL; BIOLOGICAL MODEL; CHEMICAL MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METABOLISM; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

HUMAN IMMUNODEFICIENCY VIRUS;

ADMINISTRATION, ORAL; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NELFINAVIR; RITONAVIR; SAQUINAVIR;

EID: 1842833729     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.12.1455     Document Type: Article

References (30)

1. Barry M and Feely J (1990) Enzyme induction and inhibition. Pharmacol Ther 48:71-94.
2. Barry M, Gibbons S, Back D, and Mulcahy F (1997) Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations. Clin Pharmacokinet 32:194-209.
3. Beal SL and Sheiner LB (1989-1998) NONMEM User's Guide. University of California San Francisco. San Francisco, CA.
4. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
5. Buss N (2000) Effect of ritonavir on saquinavir metabolism. J Am Med Assoc 283:2936-2937.
6. Cox DR and Hinkley DV (1974) Theoretical Statistics. Chapman & Hall, London.
7. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
8. Eagling VA, Profit L, and Back DJ (1999) Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48:543-552.
9. Faulds D and Jarvis B (1998) Nelfinavir: A review of its therapeutic efficacy in HIV infection. Drugs 56:147-167.
10. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
11. Gorski JC, Hall SD, Jones DR, VandenBranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
12. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, and Shader RI (2000) Alprazolam-ritonavir interaction: Implications for product labeling. Clin Pharmacol Ther 67:335-341.
13. Hsu A, Granneman GR, and Bertz RJ (1998a) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275-291.
14. Hsu A, Granneman G, Can G, Carothers L. El-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, and Leonard JM (1998b) Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63:453-464.
15. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, and Schinkel AH (2001) P-glycoprotein limits oral availability, brain and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59:806-813.
16. Jarvis B and Faulds D (1998) Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs 56; 147-167.
17. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, et al. (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654-660.
18. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N, and Saag MS (2000) Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 44:2672-2678.
19. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Investig 101:289-294.
20. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552-561.
21. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, and Dey S (1998) HIV-1 protease inhibitors are subsrates for the MDRI multidrug transporter. Biochemistry 37:3594-3601.
22. Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, and Jurima-Romet M (1997) Preclinical evaluation of drug-drug interaction potential: Present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 107:5-16.
23. Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA (1998) Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609-616.
24. Merry C, Barry MG, Mulcahy F, Halifax KL, and Back DJ (1997) Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 11:17117-120.
25. Segel IH (1976) Biochemical Calculations, 2nd Ed. John Wiley and Sons, New York.
26. Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, and Nakano M (2000) Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter Pglycoproteins. Biol Pharm Bull 23:1528-1531.
27. Wacher VJ, Wu C-Y, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of Cytochrome P450, 3A and P-glycoprotein: Implications for drug delivery in cancer chemotherapy. Mol Carcinog 13:129-134.
28. Washington CB, Duran GE, Man MC, Sikic BI, and Blaschke TF (1998) Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 19:203-209.
29. Wilkinson GR and Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-379.
30. Yuan R, Parmelee T, Balian JD, Uppoor RS, Ajayi F, Burnett A, Lesko LJ, and Marroum P (1999) In vitro metabolic interaction studies: Experience of the Food and Drug Administration. Clin Pharmacol Ther 66:9-15.